Yung-Ting Cheng
Papers
1
Total Citations
9
H-Index
1
About
Yung-Ting Cheng is a leading urological researcher whose work focuses on improving the diagnosis and prognosis of prostate cancer through novel biomarkers. His major contributions center on the clinical application of the prostate health index (PHI) and its derivative, %p2PSA, to predict aggressive pathological outcomes in patients undergoing radical prostatectomy. In his landmark 2020 study, Cheng demonstrated that preoperative %p2PSA and PHI scores significantly enhance the accuracy of identifying high-risk prostate cancer, potentially reducing unnecessary surgeries. This work, cited 9 times, has influenced preoperative risk stratification protocols. Cheng’s research bridges the gap between laboratory biomarkers and surgical decision-making, offering urologists a more precise tool for predicting tumor aggressiveness. His findings are particularly valuable for patients with organ-confined disease, where overtreatment remains a clinical challenge. By validating these biomarkers in a cohort of 91 robot-assisted prostatectomy patients, Cheng has provided actionable insights that improve patient outcomes. His ongoing investigations continue to refine prostate cancer management, making him a key voice in precision oncology and urological surgery.
Research Focus
Key Achievements
Top Papers
- 1